9 citations
,
July 2021 in “Frontiers in Pharmacology” This study found that intradermal injection of cholesterol-modified siRNA targeting FGF5 or FGF18, or topical application of FGF18-targeted siRNA, effectively influenced hair follicle cycles in mice, suggesting potential benefits for alopecia management.
1 citations
,
May 2023 in “Biochemical and Biophysical Research Communications” This study found that DKK1-targeting siRNA, which may activate the Wnt/β-catenin signaling pathway, showed hair growth results in mice similar to those treated with the FDA-approved minoxidil, suggesting potential as an androgenetic alopecia therapy.
September 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” This study found that a chemically modified small-interfering RNA candidate, AR-27 E-Chol, effectively stimulated hair regrowth and reduced androgen receptor gene expression in a mouse model of androgenetic alopecia, indicating its potential as a novel therapeutic approach.
September 2025 in “Journal of Medicinal Chemistry” This study evaluated a chemically modified siRNA, AR-27 E-Chol, which effectively promoted hair regrowth and reduced androgen receptor gene expression in a DHT-induced mouse model of androgenetic alopecia, suggesting its potential as a novel therapeutic candidate.
25 citations
,
December 2017 in “The Journal of Clinical Endocrinology & Metabolism” This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.